Thus, a lack of fully functional RUNX1 or CEBPA proteins in AML patients with a corresponding mutation could prevent the interaction of TET2 with the regions around their TFBS, leading to methylation of regulatory regions and suppression of several genes’ expressions. The gene discussed is TET2; the disease is acute myeloid leukemia.